These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 23090506)

  • 1. siRNA-based therapeutic approaches for rheumatic diseases.
    Apparailly F; Jorgensen C
    Nat Rev Rheumatol; 2013 Jan; 9(1):56-62. PubMed ID: 23090506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanovehicle-based Small Interfering RNA (siRNA) Delivery for Therapeutic Purposes: A New Molecular Approach in Pharmacogenomics.
    Akhtari J; Tafazoli A; Mehrad-Majd H; Mahrooz A
    Curr Clin Pharmacol; 2018; 13(3):173-182. PubMed ID: 29992895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. siRNA: Mechanism of action, challenges, and therapeutic approaches.
    Alshaer W; Zureigat H; Al Karaki A; Al-Kadash A; Gharaibeh L; Hatmal MM; Aljabali AAA; Awidi A
    Eur J Pharmacol; 2021 Aug; 905():174178. PubMed ID: 34044011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A
    Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic face of RNAi: in vivo challenges.
    Borna H; Imani S; Iman M; Azimzadeh Jamalkandi S
    Expert Opin Biol Ther; 2015 Feb; 15(2):269-85. PubMed ID: 25399911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA interference: from gene silencing to gene-specific therapeutics.
    Leung RK; Whittaker PA
    Pharmacol Ther; 2005 Aug; 107(2):222-39. PubMed ID: 15908010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies.
    Deng Y; Wang CC; Choy KW; Du Q; Chen J; Wang Q; Li L; Chung TK; Tang T
    Gene; 2014 Apr; 538(2):217-27. PubMed ID: 24406620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA interference-based gene therapy for successful treatment of rheumatoid arthritis.
    Courties G; Presumey J; Duroux-Richard I; Jorgensen C; Apparailly F
    Expert Opin Biol Ther; 2009 May; 9(5):535-8. PubMed ID: 19392574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivering small interfering RNA for novel therapeutics.
    Lu PY; Woodle MC
    Methods Mol Biol; 2008; 437():93-107. PubMed ID: 18369963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. To Conjugate or to Package? A Look at Targeted siRNA Delivery Through Folate Receptors.
    Salim L; Desaulniers JP
    Nucleic Acid Ther; 2021 Feb; 31(1):21-38. PubMed ID: 33121373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. siRNA therapeutics: a clinical reality.
    Saw PE; Song EW
    Sci China Life Sci; 2020 Apr; 63(4):485-500. PubMed ID: 31054052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach.
    Mahmoodi Chalbatani G; Dana H; Gharagouzloo E; Grijalvo S; Eritja R; Logsdon CD; Memari F; Miri SR; Rad MR; Marmari V
    Int J Nanomedicine; 2019; 14():3111-3128. PubMed ID: 31118626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arthritic joint-targeting small interfering RNA-encapsulated liposome: implication for treatment strategy for rheumatoid arthritis.
    Komano Y; Yagi N; Onoue I; Kaneko K; Miyasaka N; Nanki T
    J Pharmacol Exp Ther; 2012 Jan; 340(1):109-13. PubMed ID: 21994423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in siRNA delivery.
    Sarisozen C; Salzano G; Torchilin VP
    Biomol Concepts; 2015 Dec; 6(5-6):321-41. PubMed ID: 26609865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene silencing of virus replication by RNA interference.
    Miyano-Kurosaki N; Takaku H
    Handb Exp Pharmacol; 2006; (173):151-71. PubMed ID: 16594615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of chemically modified siRNA: Recent trends.
    Selvam C; Mutisya D; Prakash S; Ranganna K; Thilagavathi R
    Chem Biol Drug Des; 2017 Nov; 90(5):665-678. PubMed ID: 28378934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNAi-based drug design: considerations and future directions.
    Tang Q; Khvorova A
    Nat Rev Drug Discov; 2024 May; 23(5):341-364. PubMed ID: 38570694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. siRNA delivery using nanocarriers - an efficient tool for gene silencing.
    Khurana B; Goyal AK; Budhiraja A; Arora D; Vyas SP
    Curr Gene Ther; 2010 Apr; 10(2):139-55. PubMed ID: 20353386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipidoid-polymer hybrid nanoparticles loaded with TNF siRNA suppress inflammation after intra-articular administration in a murine experimental arthritis model.
    Jansen MAA; Klausen LH; Thanki K; Lyngsø J; Skov Pedersen J; Franzyk H; Nielsen HM; van Eden W; Dong M; Broere F; Foged C; Zeng X
    Eur J Pharm Biopharm; 2019 Sep; 142():38-48. PubMed ID: 31199978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.